IGF-1 LR3 Dosing Protocol: Reconstitution, Daily Dose, and Cycle Length

Dosing — 2026-05-08

IGF-1 LR3 is the most potent IGF-1 analog in widespread research use, and its long 20–30 hour half-life makes it more practical than native IGF-1 (12–15 minute half-life) for protocol design. But that potency demands precision — sub-microgram dosing errors materially affect outcomes. This article walks through reconstitution math for the 1mg vial, common dose ranges, cycle structure, and the timing logic relative to training stimulus in research models.

Researcher special: code WELCOME at checkout unlocks 35% off IGF-1 LR3 1mg, bacteriostatic water, and the CJC-1295/Ipamorelin blend used in many growth-axis stacks. Every vial ships with a batch-matched COA at 99%+ HPLC purity.

The 1mg Vial: Reconstitution Math

IGF-1 LR3 is supplied as a 1mg lyophilized vial. The standard reconstitution and the resulting unit math:

Most research protocols reconstitute with 1 mL for simpler unit math: - 1 unit on a U-100 insulin syringe = 10 mcg - 2 units = 20 mcg - 4 units = 40 mcg - 5 units = 50 mcg

This gives you 100 dose-units of reconstituted material. At 40 mcg/day, a single 1mg vial covers 25 days of dosing.

If you want sub-10 mcg granularity (for precise dose-titration studies), use 2 mL instead. Then 1 unit = 5 mcg, and the vial covers 200 dose-units.

Common Dose Ranges in Research Protocols

The published in-vitro and animal-model literature uses doses on the order of micrograms per kilogram body weight. Common ranges seen in extended research protocols:

The 40 mcg/day number is the most common single dose in published research summaries. It's enough to noticeably elevate IGF-1R signaling without producing the hypoglycemic risk that higher doses carry.

Because IGF-1 LR3 has a 20–30 hour half-life, once-daily dosing is sufficient to maintain steady-state exposure. There's no published advantage to splitting the daily dose.

Timing: Pre- vs. Post-Training

In athletic research models, the most common timing question is whether to dose pre-training, post-training, or non-training-day. The mechanistic rationale for each:

Post-training (most common) - IGF-1R signaling synergizes with mTOR activation from resistance training - Protein synthesis rates are elevated for ~24 hours post-training - Aligns peptide peak exposure with the anabolic window - Most research protocols default to this

Pre-training - Some glycogen-sparing effects - Theoretical satellite cell priming - Less common in published protocols

Off-training days - Maintains daily dosing simplicity - Avoids any acute interaction with training-day glucose dynamics - Used when training schedule is variable

In practice, the half-life is long enough that the *exact* timing matters less than *consistency* — same time each day produces stable exposure regardless of which protocol you pick.

Cycle Length: 4 Weeks On, 4 Weeks Off

The dominant cycle structure in research protocols is 4 weeks on, 4 weeks off (sometimes 4 on / 2 off in shorter studies). The rationale:

• IGF-1R desensitization on extended exposure is real
• Off-cycle weeks restore receptor density
• Endogenous IGF-1 axis recovery is faster after shorter cycles
• 4 weeks is long enough for measurable cellular endpoints, short enough to avoid receptor downregulation

Some longer protocols use 6 weeks on / 4 weeks off for endpoints requiring sustained exposure. Continuous administration beyond 6–8 weeks is uncommon in research designs because the marginal effect plateaus.

A typical 4-week cycle at 40 mcg/day uses roughly 1.1mg total — a single 1mg vial covers a cycle with negligible margin, so most protocols allocate 2 vials per cycle to avoid running short.

Side Effects to Watch

IGF-1 LR3 is potent. Common adverse effects in the published research:

• Hypoglycemia — most common, especially at higher doses or fasting state. Subjects should not dose without recent food intake, particularly during the first week.
• Injection site reactions — mild redness, lump formation at SQ sites
• Joint discomfort — IGF-1 elevation systemically can produce GH-class arthralgia
• Numbness or tingling — rare, dose-dependent
• Tissue growth concerns — IGF-1 is broadly mitogenic; subjects with active or history of malignancy are not candidates

Hypoglycemia is the dominant concern. A subject reconstituting at 1 mg/mL who accidentally draws 10 units instead of 4 has dosed 100 mcg instead of 40 — that error can produce symptomatic hypoglycemia. Always re-check the syringe before injection.

Storage

• Lyophilized: -20°C for long-term stability; 2–8°C acceptable short-term
• Reconstituted: 2–8°C, stable for ~14 days under bacteriostatic water
• Avoid freeze-thaw cycles of reconstituted material — splits the protein

For protocols longer than 14 days, reconstitute one vial at a time as needed rather than reconstituting the whole supply at once. See our peptide storage guide for stability details.

Stacking: Beyond Standalone

Most modern research protocols don't use IGF-1 LR3 in isolation. The most common pairings:

• CJC-1295 + Ipamorelin — drives endogenous GH release, which produces endogenous IGF-1 elevation. The combination with exogenous IGF-1 LR3 hits both ends of the GH-IGF-1 axis simultaneously.
• BPC-157 + TB-500 (Wolverine Stack) — for recovery research where IGF-1 LR3 is the anabolic driver and BPC/TB are the repair drivers
• Tesamorelin — for body-composition research, where tesa drives visceral fat loss and IGF-1 LR3 supports lean mass

See our IGF-1 LR3 stacking guide for the full mechanism overlap discussion and protocol templates.

Equipment and Supplies

A standard IGF-1 LR3 protocol uses: - 1 vial of IGF-1 LR3 1mg per 25-day cycle (allocate 2 per 4-week cycle for buffer) - 1 vial of bacteriostatic water 10mL (covers many reconstitutions) - U-100 insulin syringes — the dose granularity matters; don't substitute larger syringes - Alcohol swabs for vial tops and injection sites

Sourcing

Code WELCOME at checkout unlocks 35% off IGF-1 LR3 1mg, bacteriostatic water, and the CJC-1295 + Ipamorelin blend used in the most common growth-axis stacks. Every vial ships with a batch-matched COA showing 99%+ HPLC purity, US-based handling, and the per-mg potency consistency that makes accurate sub-microgram dosing possible. For the full peptide profile and study summary, see our IGF-1 LR3 research overview.

Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.